Genmab A/S Stock

Genmab A/S Operating Cash Flow

The Operating Cash Flow of Genmab A/S (GMAB.CO) as of Aug 6, 2026 is 1.19 B USD. In the previous year, Operating Cash Flow was 1.13 B USD — a change of 5.23% (higher).

Operating Cash Flow

1.19 BUSD

YoY

5.23%

Last updated:

Operating Cash Flow of Genmab A/S is 2026 1.19 B USD. Operating Cash Flow of Genmab A/S was 2025 1.13 B USD. It decreases by 5.23% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Operating Cash Flow of Genmab A/S is 1.19 B USD in 2026.

Operating Cash Flow of Genmab A/S changed from 1.13 B USD to 1.19 B USD, representing a 5.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Genmab A/S

All Key Metrics — Genmab A/S